Immunization

Data has indicated a potential association between COVID-19 vaccination and menstruation, but there is little evidence about this association based on chart-reviewed medical record data.

The estimated efficacy of the vaccine against documented infection for children and adolescents during the Omicron wave was 74.3% and 85.5%, respectively.

Study authors noted that intranasal vaccine delivery could offer benefits such as needle-free administration and induction of mucosal immunity.

A model showed that if a vaccine coverage of 66% were achieved—similar to flu vaccination coverage—it could have a budget impact of $6.48 to $6.78 billion over the first RSV season.

The vaccine, called mRNA-1345, demonstrated an efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least 2 signs or symptoms and 82.4% against the disease with at least 3 signs or symptoms.

Study authors theorized that the reduced effect could be due to disease-related or immunosuppressive treatment factors.

Check out our recap of last year's advancements made in the vaccine, biosimilar, and therapeutic spaces.

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

In January 2024, Sanofi and AstraZenenca will release 230,000 additional doses of nirsevimab-alip, heeding guidance from the CDC to leverage all tools to increase immunizations against RSV.

Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.

A Q&A with Robert Walker, MD, senior vice president and chief medical officer at Novavax.

Study results outlined in a poster at ASHP Midyear 2023 revealed that virtual delivery education programs could contribute to a more inclusive and accessible health care information landscape for Black older adults.

Vaccinated study participants experienced fewer and less persistent symptoms, as well as fewer work hours lost, compared to unvaccinated participants.

Study authors recommend that healthcare personnel consider prioritizing influenza vaccination for patients with recent cardiovascular diseases (CVDs) in light of new evidence.

VAERS was designed to collect reports of symptoms, diagnoses, hospital admissions, and deaths after vaccination for postmarket safety signals.

Ixchiq was approved through the FDA Accelerated Approval pathway.

Mebella is another weapon in the global fight to eradicate these diseases.

In a recent Morbidity and Mortality Weekly Report (MMWR), the results of a study showed 63% of those who died from HAV had at least 1 documented preexisting indication for vaccination.

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

Care home staff play a role in transmission to elderly residents by bringing flu in from their communities, especially in winter. Vaccination can combat this risk, but not all care workers get flu shots.

A new study adds to previous research that has found religious and political correlations between vaccine beliefs and hesitancy, which have geographical links.

Learn about best practices in identifying high-risk patients for COVID-19 complications. This video empowers healthcare providers with the knowledge to proactively address and manage complex COVID-19 cases effectively. Stay ahead in the ever-evolving landscape of healthcare by unlocking key strategies that enhance patient outcomes and contribute to the collective effort in preventing COVID-19 complications.

Empower your practice with the tools to combat vaccine hesitancy. This informative video tackles the nuanced challenges of addressing vaccine hesitancy, offering healthcare providers valuable strategies to engage with patients and build trust in vaccination. Enhance your communication skills, navigate common concerns, and contribute to the broader mission of achieving widespread immunity against COVID-19 with this video.

Stephen L. Foster, PharmD, FAPhA, FNAP, discussed the new vaccine and RSV prevalence at the National Community Pharmacists Association 2023 Convention and Expo.

Research findings may support further COVID-19 vaccination in children.

Jean-Venable R. Goode, PharmD, director of the PGY1 Community Based Residency Program at Virginia Commonwealth University, discussed the new vaccine guidelines from ACIP.

Based on data from an ongoing clinical trial and other studies, the R21 vaccine has been shown to have a high degree of efficacy when administered just before the high transmission season, with data showing a 75% reduction in cases of malaria in the 12 months following the 3-dose series.

During a podcast hosted by Permanente Medicine, Sandra Fryhofer, MD, chair-elect of the Board of Trustees for the American Medical Association and a liaison to the CDC’s Advisory Committee on Immunization Practices, discussed the importance of vaccines for the fall and winter seasons.

Moderna plans to begin a phase 3 trial of the combination vaccine this year.